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Streptococcus pneumoniae is the leading cause of commu-
nity-acquired pneumonia (CAP) worldwide and a major cause
of morbidity and mortality.1 S. pneumoniae is probably also
the leading cause of pneumonia of unknown etiology. The role
of microbiological tests is in the detection of an etiologic
agent causing infection so that directed therapy is possible.
However, the diagnosis of pneumococcal infections relies
heavily on culture of S. pneumoniae from blood or other
normally sterile fluids and is limited by prior administration
of antibiotics.2 For these reasons, causative pathogens may
remain unidentified in up to 50% of patients and broad-
spectrum antibiotic therapy may be continued unnecessarily
for prolonged periods of time.
The recent study by Genne et al. has shown that detection
of urinary pneumococcal antigen by using the Binax NOW S.
pneumoniae antigen test (immunochromatographic test
(ICT)) is a useful technique for the rapid diagnosis of pneu-
mococcal infections in adults.3 We performed a retrospective
study to investigate the performance of the ICT by use of
selected non-concentrated urine samples from adult CAP
patients. Approval to conduct the study was obtained from
the St Elisabeth Hospital Ethics Committee.
The CAP patients were included in the study only if a urine
sample was obtained within 48 h after hospital admission. The
cases were adult patients (>16 years of age) fromwhom blood
cultures grew S. pneumoniae (n = 52), or patients for whom
pneumococcal pneumoniawas confirmedwith positive sputum
culture results (n = 6). Controls (n = 136) were selected from
adult patients presenting with lower respiratory tract infec-
tions. A large proportion of the urine samples were obtained
from patients with proven legionnaires’ disease (n = 98)
according to criteria used by the European Working Group
on Legionella Infections (EWGLI; www.ewgli.org). The labora-
tory results of the remaining control patients were as follows:
Haemophilus influenzae (n = 10), Moraxella catarrhalis
(n = 3), Staphylococcus aureus (n = 4), Escherichia coli
(n = 2), Acinetobacter baumannii (n = 1), Streptococcus pyo-
genes (n = 2), Klebsiella pneumoniae (n = 1), Mycobacterium
tuberculosis (n = 3), Pneumocystis jirovecii (n = 1). Eleven
patients were included who had a four-fold rise or more in
complement-fixating antibodies against influenza A virus
(n = 2), adenovirus (n = 1), Chlamydia psittaci (n = 3), Myco-
plasma pneumoniae (n = 4), and parainfluenza virus (n = 1).Fifty-eight cases (median age 55 years; range 16—85 years)
and 136 controls (median age 56 years; range 16—84 years)
were included. Pneumococcal urinary antigen was positive
(after 15minutes reading) in 40 of 58 pneumococcal cases and
in three of 136 controls, giving a test sensitivity of 69% (95% CI
58—78%) and a test specificity of 98% (95% CI 93—99%) overall.
The frequencyofantigendetectionwasgreater forbacteremic
pneumococcal pneumonia (38/52 (73%)) than for non-bactere-
mic pneumococcal pneumonia (2/6 (33%)) (p = 0.07).
Of the three false-positive results in our study, two
occurred in patients who might be considered at high risk
for pneumococcal infection. One patient was a 78-year old
female admitted to the hospital with renal impairment,
malaise, fever, and shortness of breath. Chest radiography
showed extensive bilateral consolidation of the lung. Blood
cultures remained negative and in a sputum sample Haemo-
philus influenzae was cultured. She died a week after admis-
sion to the hospital. The second patient was a 31-year old HIV
positive female admitted with a respiratory tract infection
and a consolidation on chest radiograph. Blood and sputum
cultures were obtained but remained negative. Her condition
improved after initiation of amoxicillin therapy (1000 mg iv
per 6 hours) and she later showed a four-fold rise in comple-
ment-fixating antibodies against influenza A virus. The third
patient was a 42-year old female admitted with an acute
exacerbation of chronic pulmonary disease and blood cul-
tures yielding Haemophilus influenzae. None of these
patients had nasopharyngeal swabs taken to detect pneumo-
coccal carriage. It is possible that these patients had co-
infection with S. pneumoniae.
Although selection bias may possibly have affected our
sensitivity and specificity results, our findings indicate that
the sensitivity of the test is about 75% when positive blood
cultures are used as the ‘gold standard’. These findings are
similar to those of other investigators who have used the NOW
S. pneumoniae urinary antigen test. Murdoch et al. studied
420 adults with CAP, including 20 patients with pneumococcal
bacteremia, 16 (80%) of whom had detectable urinary anti-
gen levels.4 In determining the test specificity, Murdoch et al.
used 169 adult control patients with an admission diagnosis
other than a respiratory or infectious disease and found that
none had detectable pneumococcal antigen (specificity
100%). Dominguez et al. detected pneumococcal antigen in
urine specimens of 82% of 28 patients with bacteremic
pneumococcal pneumonia.5 The study by Dominguez et al.
also used control patients with pneumonia or bacteremia due
to other organisms and reported a test specificity of 97% (2/
71 tests positive). In the study by Genne et al., 67 adults with
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tract infection to determine sensitivity and specificity of the
ICT.3 An etiology could be found for 22 patients (33%) using
conventional methods and increased to 33 patients (49%)
with the addition of the urinary antigen test. Nine out of 14
patients diagnosed with S. pneumoniae as the etiologic agent
for their CAP had detectable urinary antigen levels (sensi-
tivity 64%; 1/81 positive control urine samples, specificity
99%). Pneumococcal infection was diagnosed by ICT in 24%
without an etiologic identification by conventional methods.
ICT appears to be a promising supplement to blood and
sputum culturing for the etiology in adult CAP. Given its high
specificity, this test can be considered an important tool for
detecting S. pneumoniae in CAP. As such, these assays can
have important implications for the choice of first-line anti-
biotic therapy in patients with CAP. Although antibiotic
treatment active against atypical pathogens is routinely
recommended in CAP guidelines, such treatment was found
not to be superior to beta-lactammonotherapy, unless Legio-
nella species was the cause of infection, in two recent meta-
analyses of the treatment of CAP.6,7 Recently, Guchev et al.8
demonstrated that amoxicillin treatment could successfully
be targeted by use of the ICT in non-severe CAP. Stra˚lin and
Holmberg9 showed that patients with positive ICTresults had
a significantly higher success rate using beta-lactam mono-
therapy than did patients with negative results (success rate
ICT positive patients: 92% (35/38), success rate ICT negative
patients: 76% (87/114); p = 0.034). Therefore, a positive ICT
result can support treatment with narrow-spectrum beta-
lactam antibiotics and can be used to prevent unnecessary
broad antibiotic changes. In patients with severe CAP and a
negative ICT result, diagnostic tests for conventional and
atypical pathogens, including a urinary antigen test for the
detection of Legionella pneumophila serogroup 1, are useful
to gain support for the ongoing treatment or to suggest
treatment alterations.
Conflict of interest: No conflict of interest to declare.
References
1. File TM. Community-acquired pneumonia. Lancet 2003;362:
1991—2001.
2. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, et al.
Guidelines for the management of adult lower respiratory tract
infections. Eur Respir J 2005;26:1138—80.3. Genne D, Siegrist HH, Lienhard R. Enhancing the etiologic
diagnosis of community-acquired pneumonia in adults using the
urinary antigen assay (Binax NOW). Int J Infect Dis 2006;10:
124—8.
4. Murdoch DR, Laing RT, Mills GD, Karalus NC, Town GI, Mirrett S,
et al. Evaluation of a rapid immunochromatographic test for
detection of Streptococcus pneumoniae antigen in urine samples
from adults with community-acquired pneumonia. J Clin Micro-
biol 2001;39:3495—8.
5. Dominguez J, Gali N, Blanco S, Pedroso P, Prat C, Matas L, et al.
Detection of Streptococcus pneumoniae antigen by a rapid immu-
nochromatographic assay in urine samples. Chest 2001;119:
243—9.
6. Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam anti-
biotics compared with antibiotics active against atypical patho-
gens in non-severe community acquired pneumonia: meta-
analysis. BMJ 2005;330:456.
7. Shefet D, Robenshtock E, Paul M, Leibovici L. Empiric antibiotic
coverage of atypical pathogens for community acquired pneumo-
nia in hospitalized adults. Cochrane Database Syst Rev 2005:
CD004418.
8. Guchev IA, Yu VL, Sinopalnikov A, Klochkov OI, Kozlov RS, Stratch-
ounski LS. Management of nonsevere pneumonia in military trai-
nees with the urinary antigen test for Streptococcus pneumoniae:
an innovative approach to targeted therapy. Clin Infect Dis
2005;40:1608—16.
9. Stra˚lin K, Holmberg H. Usefulness of the Streptococcus pneumo-
niae urinary antigen test in the treatment of community-acquired
pneumonia. Clin Infect Dis 2005;41:1209—10.
Bram M.W. Diederen*
Marcel F. Peeters
Laboratory of Medical Microbiology and Immunology,
St Elisabeth Hospital,
PO Box 747, 5000 AS Tilburg,
The Netherlands
*Corresponding author. Tel.: +31 13 539 2655;
fax: +31 13 544 1264
E-mail address: bramdiederen@gmail.com
(B.M.W. Diederen)
Corresponding Editor: Timothy Barkham, Singapore
30 May 2006
doi:10.1016/j.ijid.2006.07.006
